Amarin: Some Investment Strategies For 2020
Summary
- In recent news, Amarin's legal brief has been filed, and generic Vascepa has been FDA-approved.
- We covered the legal brief extensively in a number of articles.
- This article discusses some investment strategies for AMRN based on the above developments.
- Looking for more stock ideas like this one? Get them exclusively at The Total Pharma Tracker. Get started today »
Update: The following strategy article was written around 10 days ago and provided to TPT members. Since then, there has been a single significant change - the FDA has approved an ANDA from Hikma, bringing generic competition closer to the market. This news, in its turn, has had two major impacts - one, the stock has fallen briefly, from near $8 to now a little below $7; however, clarity on the legal front, as we showed in our coverage (here, here and here), seems to have helped the options arena turn more active.
We observe significant changes in option price (upto $0.5 for both call and put options) within strike price of $6 & $8. We may assume investors have become more active and are trying to cover their bullish or bearish positions respectively by buying or selling calls and puts around the current market price.
In addition, more December Call and Put options have been initiated between $3 -$5 in the lower side and $10-$15 on the upper side.
In order to reflect these significant changes, we have updated the entire strategy scenario for AMRN.
-----
Amarin (NASDAQ:AMRN) has a few tumultuous months ahead as the appeal they filed goes through the process. As noted in my previous articles, the timeline is going to be like this:
As we are expecting a judgement in favor of Amarin by late October or early November, we expect remarkable price movement by that time. By considering call and put options dated December 18, 2020, we formulated pay off from different option trading strategies. As we expect the price of AMRN to remain within a range of $3.5 to $18.5 per share, our option trading strategies involve call and put options within a strike price of $3 to $15 (the highest available strike price).
We found that only the vertical bullish spread strategy may provide positive cash flow under any circumstance. However, the cash flow is significantly low, ranging between $0.16 and $1.16. Thus, it does not suit an average investor who'll be more interested to generate profit than to generate a minimal positive cash flow. However, this strategy may be considered by a risk averse person trying to make some earnings without any investment.
If we are reasonably bearish, and don't expect the price to go down below $5.77, then we can surely go for covered call strategy, as it provides good profitability and very low breakeven. As we are quite optimistic of price not nose dipping from the current level, covered call can be opted by bullish investors. However, it has some loss potential in case the judgement goes entirely against Amarin.
With strategies like straddle, strips, or protective put, we are able to generate positive cash flows in case the stock makes significant movement upwards more specifically when it crosses $10, which we also expect to happen. However, the losses expected in adverse scenario (below $10) are quite significant for straddle and strips, whereas it is limited to $0.15 for protective put. Thus, in order to minimize losses while being bullish on the stock, protective put will be the most desired strategy.
Thus, our desired strategy will be a protective put in which we would buy AMRN stock @$6.85 and buy a December put option at $11 per share, at a premium of $4.3.
Covered Call: Buying AMRN stock @$6.85 and writing an AMRN December call option at $15 per share, and at a premium of $1.08, thus having an initial cash outflow of $5.77.
Market Price | Cash Inflow from Stock | Cash Inflow from Option | Cash Outflow | Net Cash Flow |
2 | 2 | 0 | 5.77 | -3.77 |
4 | 4 | 0 | 5.77 | -1.77 |
6 | 6 | 0 | 5.77 | 0.23 |
8 | 8 | 0 | 5.77 | 2.23 |
10 | 10 | 0 | 5.77 | 4.23 |
12 | 12 | 0 | 5.77 | 6.23 |
14 | 14 | 0 | 5.77 | 8.23 |
16 | 16 | -1 | 5.77 | 9.23 |
18 | 18 | -3 | 5.77 | 9.23 |
20 | 20 | -5 | 5.77 | 9.23 |
Protective Put: Buying AMRN stock at $6.85 per share, and buying an AMRN December put option at $11 per share at a premium of $4.3, thus having an initial cash outflow of $11.15
Market Price | Cash Inflow from Stock | Cash Inflow from Option | Cash Outflow | Net Cash Flow |
2 | 2 | 9 | 11.15 | -0.15 |
4 | 4 | 7 | 11.15 | -0.15 |
6 | 6 | 5 | 11.15 | -0.15 |
8 | 8 | 3 | 11.15 | -0.15 |
10 | 10 | 1 | 11.15 | -0.15 |
12 | 12 | 0 | 11.15 | 0.85 |
14 | 14 | 0 | 11.15 | 2.85 |
16 | 16 | 0 | 11.15 | 4.85 |
18 | 18 | 0 | 11.15 | 6.85 |
20 | 20 | 0 | 11.15 | 8.85 |
Straddle: Buying/Selling a call and put option with the same exercise price and the same expiration date. The maximum loss for a straddle buyer is the option premium in both the options.
e.g. Buying AMRN December call at $6 per share, and buying an AMRN December put option at $6 per share at a premium of $2.85 and $1.65 respectively, thus having an initial cash outflow of $4.5.
Market Price | Cash Inflow from Call | Cash Inflow from Put | Cash Outflow | Net Cash Flow |
2 | 0 | 4 | 4.5 | -0.5 |
4 | 0 | 2 | 4.5 | -2.5 |
6 | 0 | 0 | 4.5 | -4.5 |
8 | 2 | 0 | 4.5 | -2.5 |
10 | 4 | 0 | 4.5 | -0.5 |
12 | 6 | 0 | 4.5 | 1.5 |
14 | 8 | 0 | 4.5 | 3.5 |
16 | 10 | 0 | 4.5 | 5.5 |
18 | 12 | 0 | 4.5 | 7.5 |
20 | 14 | 0 | 4.5 | 9.5 |
Strangle: Buying/Selling a call and put option with the different exercise price and the same expiration date. The strike price of call option should be higher than the strike price of put option.
e.g. Buying AMRN December call at $15 per share, and buying an AMRN December put option at $3 per share at a premium of $1.08 and $0.12 (bid price) respectively, thus having an initial cash outflow of $1.2.
Market Price | Cash Inflow from Call | Cash Inflow from Put | Cash Outflow | Net Cash Flow |
2 | 0 | 1 | 1.2 | -0.2 |
4 | 0 | 0 | 1.2 | -1.2 |
6 | 0 | 0 | 1.2 | -1.2 |
8 | 0 | 0 | 1.2 | -1.2 |
10 | 0 | 0 | 1.2 | -1.2 |
12 | 0 | 0 | 1.2 | -1.2 |
14 | 0 | 0 | 1.2 | -1.2 |
16 | 1 | 0 | 1.2 | -0.2 |
18 | 3 | 0 | 1.2 | 1.8 |
20 | 5 | 0 | 1.2 | 3.8 |
Butterfly Spread: Buying one call option at higher strike price, buying one call option at a lower strike price, and selling two call options at a same intermediate strike price. The options are of same expiration date, and on same underlying asset. Here, the person is trying to play safe and is neither bullish nor bearish
e.g. Buying AMRN December call at $15 per share, buying AMRN December call at $4 per share and selling two AMRN December call options at $6 per share at a premium of $1.08, $3.97, $5.7 respectively thus having an initial cash inflow of $0.65.
Market Price | Cash Inflow from $4 Call | Cash Inflow from $15 Call | Cash Inflow from $6 Call | Initial Cash Inflow | Net Cash Flow |
2 | 0 | 0 | 0 | 0.65 | 0.65 |
4 | 0 | 0 | 0 | 0.65 | 0.65 |
6 | 2 | 0 | 0 | 0.65 | 2.65 |
8 | 4 | 0 | -4 | 0.65 | 0.65 |
10 | 6 | 0 | -8 | 0.65 | -1.35 |
12 | 8 | 0 | -12 | 0.65 | -3.35 |
14 | 10 | 0 | -16 | 0.65 | -5.35 |
16 | 12 | 1 | -20 | 0.65 | -6.35 |
18 | 14 | 3 | -24 | 0.65 | -6.35 |
Strips: Buying/Selling a call option and two put options with the same exercise price and the same expiration date. The maximum loss for a strip buyer is the option premiums, but here the buyer is more bearish.
e.g. Buying AMRN December call at $5 per share, and buying two AMRN December put option at $5 per share at a premium of $3.45 (bid price) and $1.96 respectively, thus having an initial cash outflow of $5.41.
Market Price | Cash Inflow from Call | Cash Inflow from Put | Cash Outflow | Net Cash Flow |
2 | 0 | 6 | 5.41 | 0.59 |
4 | 0 | 2 | 5.41 | -3.41 |
6 | 1 | 0 | 5.41 | -4.41 |
8 | 3 | 0 | 5.41 | -2.41 |
10 | 5 | 0 | 5.41 | -0.41 |
12 | 7 | 0 | 5.41 | 1.59 |
14 | 9 | 0 | 5.41 | 3.59 |
16 | 11 | 0 | 5.41 | 5.59 |
18 | 13 | 0 | 5.46 | 7.59 |
Straps: Buying/Selling two call options and one put option with the same exercise price and the same expiration date. The maximum loss for a strap buyer is the option premiums, but here the buyer is more bullish.
e.g. Buying 2 AMRN December call at $11 per share, and buying one AMRN December put option at $11 per share at a premium of $2.74 and $4.62 respectively, thus having an initial cash outflow of $7.36.
Market Price | Cash Inflow from Call | Cash Inflow from Put | Cash Outflow | Net Cash Flow |
2 | 0 | 9 | 7.36 | 1.64 |
4 | 0 | 7 | 7.36 | -0.36 |
6 | 0 | 5 | 7.36 | -2.36 |
8 | 0 | 3 | 7.36 | -4.36 |
10 | 0 | 1 | 7.36 | -6.36 |
12 | 2 | 0 | 7.36 | -5.36 |
14 | 6 | 0 | 7.36 | -1.36 |
16 | 10 | 0 | 7.36 | 2.64 |
18 | 14 | 0 | 7.36 | 6.64 |
Vertical Bullish spread: Buying a call option at lower strike price and selling another call option at higher strike price at the same expiration date. Here, the person is expecting the price to go up.
e.g. Buying one AMRN December call at $12 per share, and selling one AMRN December call option at $13 per share at a premium of $1.22 and $1.38 respectively, thus having an initial cash inflow of $0.16.
Market Price | Cash Inflow from $12 Call | Cash Inflow from $13 Call | Cash inflow | Net Cash Flow |
2 | 0 | 0 | 0.16 | 0.16 |
4 | 0 | 0 | 0.16 | 0.16 |
6 | 0 | 0 | 0.16 | 0.16 |
8 | 0 | 0 | 0.16 | 0.16 |
10 | 0 | 0 | 0.16 | 0.16 |
12 | 0 | 0 | 0.16 | 0.16 |
14 | 2 | -1 | 0.16 | 1.16 |
16 | 4 | -3 | 0.16 | 1.16 |
18 | 6 | -5 | 0.16 | 1.16 |
Vertical Bearish spread: Buying a call option at higher strike price and selling another call option at lower strike price at the same expiration date. Here, the person is expecting the price to go down.
e.g. selling AMRN December call at $10 per share, and buying one AMRN December call option at $11 per share at a premium of $1.8 and $1.37 respectively, thus having an initial cash inflow of $0.43.
Market Price | Cash Inflow from $10 Call | Cash Inflow from $11 Call | Cash Inflow | Net Cash Flow |
2 | 0 | 0 | 0.43 | 0.43 |
4 | 0 | 0 | 0.43 | 0.43 |
6 | 0 | 0 | 0.43 | 0.43 |
8 | 0 | 0 | 0.43 | 0.43 |
10 | 0 | 0 | 0.43 | 0.43 |
12 | -2 | 1 | 0.43 | -0.57 |
14 | -4 | 3 | 0.43 | -0.57 |
16 | -6 | 5 | 0.43 | -0.57 |
18 | -8 | 7 | 0.43 | -0.57 |
Condor Spread: Buying one call option at higher strike price, buying one call option at a lower strike price, and selling two call options at two different intermediate strike price. The options are of same expiration date, and on same underlying asset.
Here, the person is trying to play safe and is neither bullish nor bearish
e.g. Buying AMRN December call at $15 per share and $4 per share and selling September call options at $6 per share and $7 per share, at a premium of $1.08, $3.97, $2.85 and $2.55 respectively, thus having an initial cash inflow of $0.35.
Market Price | Cash Inflow from $15 call | Cash Inflow from $4 call | Cash Inflow from $6Call | Cash Inflow from $7 Call | Initial Cash Inflow | Net Cash Flow |
2 | 0 | 0 | 0 | 0 | 0.35 | 0.35 |
4 | 0 | 0 | 0 | 0 | 0.35 | 0.35 |
6 | 0 | 2 | 0 | 0 | 0.35 | 2.35 |
8 | 0 | 4 | -2 | 0 | 0.35 | 2.35 |
10 | 0 | 6 | -4 | -3 | 0.35 | -0.65 |
12 | 0 | 8 | -6 | -5 | 0.35 | -2.65 |
14 | 0 | 10 | -8 | -7 | 0.35 | -4.65 |
16 | 1 | 12 | -10 | -9 | 0.35 | -5.65 |
18 | 3 | 14 | -12 | -11 | 0.35 | -5.65 |
If you want to keep yourself on top of the Amarin situation, subscribe to the Total Pharma Tracker. My focus coverage universe is small, but those few stocks that I cover in depth, I go everywhere and see everything - and TPT subscribers read it first.
This article was written by
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
Analyst’s Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in AMRN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.